Fenghua Wu | Oncology Pharmaceuticals | Best Researcher Award

Fenghua Wu | Oncology Pharmaceuticals | Best Researcher Award

Mrs. Fenghua Wu at Hubei university of chinese medcine, China.

Mrs. Fenghua Wu is a distinguished researcher and educator with a doctoral degree from Tongji Medical College, Huazhong University of Science and Technology šŸŽ“. She specializes in physiology and oncology, focusing on the tumor microenvironment and tumor immunology šŸ”¬. Her groundbreaking research explores the regulatory mechanisms of natural and traditional Chinese medicines in cancer treatment 🌿. As a principal investigator for the National Natural Science Foundation of China, she has published extensively in SCI-indexed journals šŸ“š. Honored as a “Teaching Expert” and COVID-19 frontline contributor šŸ…, she also serves as a Guest Editor for Frontiers in Immunology.

Publication ProfileĀ 

Scopus

Education

Mrs. Fenghua Wu earned her doctoral degree from Tongji Medical College, Huazhong University of Science and Technology šŸ„. She currently teaches physiology and is actively engaged in oncology research šŸ”¬ at her institution. Her work focuses on exploring cancer biology and its treatment mechanisms. As a leading scientist, she has served as the principal investigator for prestigious projects funded by the National Natural Science Foundation of China šŸ‡ØšŸ‡³. Her academic dedication and scientific contributions reflect her commitment to advancing knowledge in the field of cancer research and education.

Professional Memberships

Mrs. Fenghua Wu is a proud member of the Chinese Anti-Cancer Association (CACA) 🧬, a prestigious national organization committed to advancing cancer research, treatment, and public health awareness in China šŸ‡ØšŸ‡³. Her affiliation with CACA underscores her dedication to the oncology field and her active participation in collaborative efforts aimed at combating cancer through scientific innovation and knowledge exchange šŸ”¬. As part of this professional body, she stays connected with leading experts, contributes to cancer-related initiatives, and continuously enhances her expertise to benefit patients and students alike.

Research FocusĀ 

Mrs. Fenghua Wu’s research focus lies at the intersection of tumor immunology, traditional Chinese medicine, and molecular oncology 🧬. She explores how natural compounds—such as dihydroartemisinin and capsaicin—can modulate immune responses and inhibit cancer progression, particularly in breast cancer and tongue squamous cell carcinoma (TSCC) šŸŽÆ. Her studies often center on critical pathways like TNF-α, PI3K/AKT/mTOR, and TGF-β1, highlighting her commitment to advancing immunotherapy and targeted therapies 🧪. Her category of research can be broadly classified under Cancer Pharmacology, Immuno-Oncology, and Natural Product-Based Therapeutics.

Publication Top Notes

  • Dihydroartemisinin restrains angiogenesis through the TNF-α pathway to enhance the efficacy of anti-PD-1 immunotherapy in breast cancer
  • Capsaicin combined with cisplatin inhibits TGF-β1-induced EMT and TSCC cells migration via the Claudin-1/PI3K/AKT/mTOR signaling pathway

ATSUSHI HOSUI | Oncology Pharmaceuticals | Pharmaceutical Excellence Award

ATSUSHI HOSUI | Oncology Pharmaceuticals | Pharmaceutical Excellence Award

Dr. ATSUSHI HOSUI, Osaka Rosai Hospital, Japan

Dr. Atsushi Hosui, a distinguished hepatologist, earned his M.D. from Osaka University in 1994 šŸŽ“. With Japanese Medical License #363021, he holds multiple board certifications in internal medicine, gastroenterology, and hepatology šŸ„. Currently serving as Director of Hepatology at Osaka Rosai Hospital, he has led and contributed to numerous clinical trials on NASH, MASH, PBC, and liver cancer 🧬. A member of Japan’s leading medical societies, he is also GCP-trained (2015) šŸ“‹. Renowned for his impactful research and over 30 scientific publications, Dr. Hosui is a trailblazer in liver disease therapeutics and pharmaceutical excellence.

Publication ProfileĀ 

Scopus

Education

Dr. Atsushi Hosui embarked on his medical journey at the prestigious Osaka University, Japan šŸ—¾, where he earned his Doctor of Medicine (M.D.) degree in March 1994 šŸŽ“. Renowned for its excellence in medical education and research, Osaka University provided him with a solid foundation in clinical medicine and scientific inquiry 🧪. His education laid the groundwork for a remarkable career in gastroenterology and hepatology šŸ„. Driven by a passion for improving liver health, Dr. Hosui has since become a respected physician, researcher, and clinical investigator, dedicated to advancing pharmaceutical science and patient care globally.

Awards

Dr. Atsushi Hosui holds a prestigious Japanese Medical License (#363021) šŸ‡ÆšŸ‡µ, validating his long-standing commitment to clinical excellence. He is a board-certified member and specialist of the Japanese Society of Internal Medicine 🧬, where he also serves as an advising doctor šŸ‘Øā€āš•ļø. His specialization extends to gastroenterology and hepatology, holding certified status from the Japanese Society of Gastroenterology šŸ„, the Japan Society of Hepatology šŸ†, and the Japan Gastroenterological Endoscopy Society šŸ”¬. These recognitions underscore his expertise in digestive health and liver diseases, reflecting a distinguished career devoted to patient care and research innovation.

Experience

Dr. Atsushi Hosui has led and contributed to numerous groundbreaking clinical research projects in hepatology and internal medicine 🧬. As an investigator or sub-investigator, he played key roles in studies on NASH (2021–2022) and MASH (2024–2025) 🩺. His focus on hypozincemia (2015), hepatocellular carcinoma (2012–2016), portal vein thrombosis (2015–2016), and PBC (2025–) highlights his expertise in liver-related conditions 🧠. He also contributed significantly to studies on thrombocytopenia and chronic hepatitis C (2013) 🧫. Dr. Hosui’s research dedication reflects his mission to improve liver health and advance pharmaceutical excellence globally.

Research Focus

Dr. Atsushi Hosui’s research is centered around hepatology and gastroenterology, with a strong emphasis on hepatocellular carcinoma (HCC) 🧫, chronic liver diseases šŸ„, and vascular complications like gastric varices and Budd-Chiari syndrome šŸ«€. His clinical investigations span topics such as portal hypertension, black esophagus, hyperglycemic complications, and the long-term risks of hepatitis B treatments 🦠. His innovative approaches combine locoregional therapies, embolization techniques, and pharmacologic interventions to enhance liver cancer outcomes šŸŽÆ. Dr. Hosui’s work bridges diagnostic precision with therapeutic advancements in liver-related pathologies, reinforcing his role as a leader in hepatic disease management.

Publication Top Notes

  • Management of Gastric Varices with Portopulmonary Venous Anastomosis: A Combined Approach Using Percutaneous Transhepatic Coil Embolization and Balloon-Occluded Retrograde Transvenous Obliteration
  • Efficacy of Adding Locoregional Therapy in ATZ/BEV-Treated Patients with Stable HCC
  • Black Esophagus in Hyperosmolar Hyperglycemic Syndrome
  • The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long-Term Administration of Nucleos(t)ide Analogs
  • Solitary Cardiac Metastasis of Hepatocellular Carcinoma
  • Hepatocellular Carcinoma Associated with Secondary Budd-Chiari Syndrome

Takuma Hayashi | Oncology Pharmaceuticals | Best Researcher Award

Takuma Hayashi | Oncology Pharmaceuticals | Best Researcher Award

Prof. Dr. Takuma Hayashi, National Hospital Organization Kyoto Medical Center, Japan

Prof. Dr. Takuma Hayashi is a renowned Japanese physician-scientist specializing in gynecologic oncology. šŸŽ“ He earned his PhD from the University of Tokyo and trained at MIT’s Whitehead Institute 🧠, contributing to Nobel-linked research. Currently a professor at Shinshu University and Section Head at Kyoto Medical Center šŸ„, his groundbreaking work on uterine leiomyosarcoma (LMS) identified LMP2 deficiency as a key biomarker šŸ”Ž. Through precision medicine and genomic profiling 🧬, his research has significantly advanced diagnostics and treatment strategies for LMS. With over 30 years of funded research, Dr. Hayashi is globally recognized for revolutionizing women’s cancer care.

Publication Profile

Scopus

Education

Prof. Dr. Takuma Hayashi is a distinguished physician-scientist known for bridging fundamental cancer research with clinical applications. šŸ‘Øā€āš•ļøšŸ”¬ He is a Professor at Shinshu University Graduate School of Medicine and Section Head at Japan’s National Hospital Organization Kyoto Medical Center. šŸŽ“šŸ„ Dr. Hayashi earned his PhD from the University of Tokyo and completed postdoctoral training at MIT’s Whitehead Institute under Dr. Rick A. Young. šŸŽ“šŸ‡ÆšŸ‡µšŸ‡ŗšŸ‡ø He contributed to Nobel Prize-linked AIDS vaccine research with Dr. David Baltimore. With over 30 years of NIH and JSPS funding, his work focuses on molecular research in uterine leiomyosarcoma and ovarian cancer, collaborating with Nobel Laureate Dr. Susumu Tonegawa.

Experience

Prof. Dr. Takuma Hayashi has pioneered precision medicine breakthroughs in uterine leiomyosarcoma (LMS) treatment. šŸ§¬šŸ’‰ His team used cancer genome panel testing to tailor therapies based on each tumor’s unique genetics. For example, immunotherapy with pembrolizumab led to significant tumor regression, while targeted treatment with pazopanib stabilized disease for months. šŸŽÆšŸ’Š Dr. Hayashi’s background from the University of Tokyo and MIT supports his innovative approach. šŸš€ His ongoing goals include developing diagnostics, launching clinical trials, expanding global collaboration, and improving patient access to genomic profiling. šŸŒšŸ’” His work offers new hope for women facing this aggressive cancer.

Research Focus

Prof. Dr. Takuma Hayashi’s research primarily focuses on molecular oncology and infectious diseases, particularly cancer biomarkers and viral infections. šŸ§¬šŸ”¬ His work on uterine leiomyosarcoma involves discovering key diagnostic biomarkers like LMP2 to improve early detection and treatment strategies in aggressive cancers. šŸ©ŗšŸŽ—ļø Additionally, Dr. Hayashi explores infectious diseases such as avian influenza and COVID-19, emphasizing the One Health approach to prevent viral spread between animals and humans. šŸ¦ šŸŒ His interdisciplinary research bridges cancer biology, immunology, and public health, aiming to develop precision medicine therapies and enhance global disease control efforts.

Publication Top Notes

THE ROLE OF LIVE BIRD MARKETS SHOULD BE EMPHASIZED IN PREVENTING THE SPREAD OF HIGHLY PATHOGENIC AVIAN INFLUENZA INFECTIONS

THE IMPORTANCE OF ONE HEALTH IN PREVENTING THE SPREAD OF HIGHLY PATHOGENIC AVIAN INFLUENZA/H5N1

Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients with Gastric Cancer Associated with Hereditary Breast and Ovarian Cancer

DEVELOPMENT OF ENDOSALPINGIOSIS IN PATIENTS WITH A HISTORY OF BREAST CANCER

High Transferability of Neutralizing Antibodies against SARS-CoV-2 to Umbilical Cord Blood in Pregnant Women Vaccinated with BNT162b2 XBB.1.5: A Retrospective Cohort Study

POTENTIAL DIAGNOSTIC BIOMARKERS FOR HUMAN MESENCHYMAL TUMORS, ESPECIALLY LMP2/Ī’1I AND CYCLIN E1/MIB1 DIFFERENTIAL EXPRESSION: PRUM-IBIO STUDY

Assoc Prof Dr. Shereen ElAzzazy|Oncology Pharmaceuticals|Best Researcher Award

Assoc Prof Dr. Shereen ElAzzazy|Oncology Pharmaceuticals|Best Researcher Award

Assoc Prof Dr. Shereen ElAzzazy at HMC, QU, WHO,Qatar

PROFILEĀ Ā 

orcid

Google scholar

Early Academic Pursuits šŸŽ“

The foundation of this individual’s career is rooted in a strong academic background. Although specific details about early education are not mentioned, the advanced roles undertaken in both pharmaceutical and medical sectors suggest a deep understanding and expertise in pharmacology, clinical pharmacy, and sterile medication preparation. Their professional journey likely began with formal education in pharmacy, complemented by continuous professional development and specialized training. The fact that they were entrusted with high-responsibility roles, such as acting pharmacy director, regulatory manager, and clinical instructor, indicates a robust educational foundation coupled with a commitment to lifelong learning.

Their association with the SAAD Training Institute, affiliated with Duke University, is an important academic highlight. This affiliation points to their exposure to global standards in pharmaceutical education and practices, which undoubtedly shaped their approach to teaching and developing competencies within their professional network.

Professional Endeavors šŸ„

SAAD Specialist Hospital, Saudi Arabia (Dec 2003 – Jun 2006)
This phase of the career showcases the breadth and depth of their professional experience in Saudi Arabia’s healthcare system, particularly within SAAD Specialist Hospital, a prominent medical institution. Initially starting as a Pediatric Clinical Pharmacist in 2003, they quickly rose through the ranks to take on more senior and specialized roles.

  • Education and Development Coordinator (Dec 2005 – Jun 2006): In this role, they focused on the educational advancement of the hospital’s healthcare professionals. This position required overseeing staff training and ensuring adherence to the latest pharmaceutical guidelines and practices, fostering an environment of continual learning and improvement.
  • Aseptic Technology Instructor, SAAD Training Institute (Jun 2004 – Jun 2006): As an instructor, they were responsible for training both pharmacists and non-pharmacists in aseptic techniques, particularly in the preparation of sterile medications. The affiliation with Duke University highlights the high standard of education and training delivered.
  • IV Room Supervisor (Jun 2004 – Jun 2006): Managing the IV Room, they oversaw sterile medication preparation for neonates, pediatric, and adult patients, dealing with complex formulations such as Total Parenteral Nutrition (TPN), chemotherapy drugs, and desensitization protocols.

These roles reflect a strong command over clinical pharmacy, sterile practices, and pharmaceutical education, making them a critical contributor to healthcare improvement in Saudi Arabia.

Governmental Hospital of Tropical Diseases, Ministry of Health, Egypt (Dec 1997 – Dec 2003)
Their role at this governmental hospital in Egypt demonstrates significant leadership and management skills within the pharmaceutical services sector.

  • Inpatient Pharmacist (Dec 1997 – Sep 2002): During this period, they were entrusted with the pharmaceutical care of inpatient services, managing medication therapy and ensuring safe medication administration.
  • Acting Pharmacy Director (Oct 2002 – Dec 2003): As Acting Pharmacy Director, they assumed full authority over the hospital’s pharmacy operations. This role required balancing clinical duties with administrative responsibilities, overseeing drug inventories, ensuring compliance with pharmaceutical regulations, and leading the pharmacy staff.

This progression in Egypt’s healthcare sector speaks to their competence, leadership abilities, and the trust placed in them to manage essential healthcare operations.

CBIC Medical, Pharmaceutical Development, and Consultation Company (Nov 2002 – Dec 2003)
In parallel with their role in Egypt’s healthcare system, they also held a position in CBIC Medical, which involved regulatory and marketing responsibilities in the pharmaceutical sector.

  • Regulatory and Marketing Manager: They were tasked with navigating complex pharmaceutical regulations while overseeing the marketing of medical products. This role required a deep understanding of both the regulatory landscape and market dynamics.
  • Clinical and Marketing Instructor: Leveraging their extensive pharmaceutical knowledge, they conducted training programs for medical representatives, teaching them about new products and re-launched products, as well as imparting advanced marketing strategies.

This role illustrates their ability to work across both clinical and commercial spheres, bridging the gap between product development, regulatory compliance, and market outreach.

Contributions and Research Focus šŸ”¬

While explicit research endeavors are not mentioned, their extensive work in teaching, sterile medication preparation, and regulatory roles highlights a career deeply rooted in evidence-based practices. Their focus on educating healthcare professionals in critical areas like aseptic techniques and sterile medication preparation indicates a dedication to improving healthcare outcomes through rigorous training.

The supervisory roles in sterile medication preparation, particularly for vulnerable populations such as neonates and pediatric patients, point to a keen interest in precision pharmacy and patient safety, areas likely to have been influenced by research in clinical pharmacology.

Accolades and Recognition šŸ…

The trust and leadership roles assigned to them—ranging from being an Acting Pharmacy Director to a supervisor and instructor at the SAAD Specialist Hospital—reflect the high regard in which they were held by their peers and employers. Their instructional role at the SAAD Training Institute, affiliated with Duke University, is a significant marker of their expertise and the recognition they received in the field of pharmaceutical education.

Impact and Influence šŸŒ

Their influence spans multiple facets of healthcare, particularly in the realms of education, clinical pharmacy, and sterile medication practices. Through teaching roles, both at SAAD and CBIC Medical, they shaped the competencies of numerous healthcare professionals, directly impacting patient safety and care quality.

As a supervisor in the preparation of sterile medications, they ensured that some of the most vulnerable patients—neonates and those undergoing chemotherapy—received safe, effective treatments. This role would have had a profound impact on patient outcomes, underscoring their influence in clinical settings.

Legacy and Future Contributions šŸ“œ

Their legacy is marked by the high standards of training and education they provided, particularly in aseptic techniques and sterile medication preparation. The knowledge they imparted to medical representatives and pharmacy staff will continue to influence healthcare practices long after their direct involvement.

šŸŽ“PublicationĀ 

Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced …

  • AuthorsĀ  Ā :Jeffrey S Weber, Reinhard Dummer, Veerle de Pril, Celeste LebbĆ©, F Stephen Hodi, MDX010‐20 Investigators
  • JournalĀ  Ā  : Cancer
  • YearĀ  Ā  Ā  Ā  Ā :2013

An evaluation of pharmacist contribution to an oncology ward in a Swedish hospital

  • AuthorsĀ  Ā :Eva RƤmme Bremberg, Christina Hising, Urban NylĆ©n, Hans Ehrsson, Staffan Eksborg
  • JournalĀ  Ā  :Journal of Oncology Pharmacy Practice
  • YearĀ  Ā  Ā  Ā  Ā :2006

The role of the pharmacist in the multidisciplinary approach to the prevention and resolution of drug-related problems in cancer chemotherapy

  • AuthorsĀ  Ā : Ahmet S Boşnak, Nevzat Birand, Ɩmer Diker, Abdikarim Abdi, Bilgen Başgut
  • JournalĀ  Ā  :Journal of Oncology Pharmacy Practice
  • YearĀ  Ā  Ā  Ā  Ā :2019

Denosumab in hypercalcemia of malignancy: a case series

  • AuthorsĀ  Ā : Amanda Dietzek, Kelly Connelly, Michael Cotugno, Sylvia Bartel, Anne M McDonnell
  • JournalĀ  Ā  :Journal of Oncology Pharmacy Practice
  • YearĀ  Ā  Ā  Ā  Ā :2015

Chinese herbal medicine for reducing chemotherapy-associated side-effects in breast cancer patients: a systematic review and meta-analysis

  • AuthorsĀ  Ā :Sha Li, Tsz-him So, Guoyi Tang, Hor-Yue Tan, Ning Wang, Bacon Fung Leung Ng, Chris Kam Wa Chan, Edwin Chau-Leung Yu, Yibin Feng
  • JournalĀ  Ā  :Frontiers in Oncology
  • YearĀ  Ā  Ā  Ā  Ā :2020